Clinical trial
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer
NCT00158886 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 8, 2001
- Completion date
- August 11, 2006
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.